Lisata, Mobileye, VF, Canada Goose, F5 Trending With Analysts

Analysts are intrested in these 5 stocks: ( (LSTA) ), ( (MBLY) ), ( (VFC) ), ( (GOOS) ) and ( (FFIV) ). Here is a breakdown of their recent ratings and the rationale behind them.

Lisata Therapeutics (ticker LSTA) has slipped off some analysts’ favorite lists as uncertainty clouds its pending takeover by Kuva Labs. Joseph Pantginis has cut the stock to Hold from Buy, noting that Kuva is reworking its financing, the tender offer has yet to start, and the risk of the deal failing has risen despite a $5 per share cash offer plus a $1 contingent value right.

The agreement’s “no shop” clause expires May 29, and Kuva would owe Lisata a $2 million breakup fee if the transaction falls apart, leaving investors in a frustrating holding pattern. Yet under the surface, Lisata’s certepetide cancer program looks increasingly valuable, with multiple mid‑stage trials advancing and regulators already aligned on a Phase 3 design in pancreatic cancer.

Lisata’s ASCEND Phase 2b trial in metastatic pancreatic ductal adenocarcinoma has already produced preliminary data from one cohort and is set to deliver full results later this year. The company has held an End‑of‑Phase‑2b meeting with the FDA, securing agreement on dose, regimen, blinding and primary endpoints, and is planning a large 650–900‑patient Phase 3 study, though the launch hinges on raising new capital.

Beyond ASCEND, the BOLSTER Phase 2a trial in the U.S. is testing certepetide in first‑ and second‑line cholangiocarcinoma and is enrolling ahead of schedule, bringing forward key data to late 2025. Additional studies in combination with neoadjuvant FOLFIRINOX for several gastrointestinal cancers, and a proof‑of‑concept study in glioblastoma, round out a broad pipeline that could re‑rate the stock once the M&A cloud clears.

For investors, Lisata has become a classic special‑situation play, where short‑term deal risk competes with long‑term drug development potential. Volume remains modest, but any resolution of the Kuva process, positive certepetide data, or new funding could act as powerful catalysts in what is currently a wait‑and‑see story.

Mobileye Global Inc. (MBLY) is a name many associate with the future of autonomous driving, but Jefferies analyst Vanessa Jeffriess is taking a much colder view. She has initiated coverage with an Underperform (Sell) rating and an $8 price target, arguing that the near‑term upside is limited and the long‑term payoff depends on a handful of highly uncertain bets.

Mobileye, majority‑owned by Intel, sells vision chips and software for driver‑assistance and autonomous systems and is deeply tied to trendy themes like robotaxis and humanoid robots. Yet Jeffriess warns that higher‑autonomy systems, expected to lift average selling prices from about 2027–2028, may not deliver the hoped‑for payoff if auto makers decide to keep more of the intelligence and IP in‑house, and if Mobileye’s dependence on Volkswagen programs proves too concentrated.

Her first key debate centers on whether mix shift to higher autonomy is already fully priced into consensus expectations. While she sees a decent growth narrative, she argues the market is underestimating competitive and customer concentration risks, especially around Volkswagen’s adoption of L2/L3 systems and the ID. Buzz robotaxi project, which needs additional program wins to build momentum.

The second debate revolves around robotaxis themselves, where Jeffriess models some revenue boost but sees wide uncertainty. Her base case assumes the VW/MOIA robotaxi rollout could add low‑single‑digit revenue upside in 2027 and ramp to the high teens by 2029, but she questions the durability of Mobileye’s business model, including its $40k upfront charge and per‑mile fees in a still‑unproven commercial ecosystem.

A third debate focuses on valuation multiples. Mobileye has already derated sharply since late 2024 and now trades between high‑growth tech and traditional auto suppliers, but Jeffriess still sees the shares as expensive relative to risk; she values base ADAS at a premium to Tier 1s, SuperVision at a discount to chip leaders, and robotaxi at parity with peers, landing on a blended EV/sales multiple of about 1.9x and reinforcing her cautious stance.

VF Corp. (VFC), the owner of Vans, The North Face and Timberland, is back in favor with analyst Sam Poser, who has executed a rare two‑notch swing from Sell to Buy. He lifted his price target from $14 to $19, arguing that even subtle improvements at Vans can move the stock sharply because investor expectations are so depressed and there is “no middle ground” in sentiment.

Poser points to signs of renewed momentum at Vans, notably the success of the LX Old Skool Pearlized Pack, as a catalyst for better‑than‑feared trends. He has raised his fiscal 2027 Vans revenue forecast from a slight decline to mid‑single‑digit growth and now expects The North Face to grow about 4.5% in FY27 as inventories remain clean and retailers stay optimistic following weather‑boosted sales.

The story is not without risk, as Poser warns that Timberland’s strength could fade in late fiscal 2027 and into 2028. The brand has become heavily reliant on the iconic 6‑inch Wheat Boot, and he believes Timberland needs to revive or reinvent older outdoor styles to broaden demand and avoid over‑dependence on a single product line that could lose appeal.

Poser also expects VF’s upcoming fourth‑quarter 2026 results to be roughly in line with guidance, with the real action coming from the company’s forward outlook. He argues that, nearly three years into CEO Bracken Darrell’s tenure, VFC must offer clear, full‑year fiscal 2027 guidance, as well as credible bridges toward longer‑term targets, if it wants to rebuild investor confidence.

Importantly, Poser calls the prior goal of reaching a 10% operating margin by fiscal 2028 “completely unachievable” under current conditions. For investors, the upgrade to Buy signals a view that the bar is now low, that incremental improvements at Vans and better communication from management could drive a meaningful rerating, even if the turnaround remains a work in progress.

Canada Goose Holdings (GOOS) is getting a modest reprieve rather than a full redemption. Analyst Sam Poser has upgraded the stock from Sell to Hold with a C$12 target, but stresses that the brand is “not a fine pâté,” and that the move is driven largely by valuation after the share price slid closer to his downside scenario.

The company’s fourth‑quarter 2026 results delivered a mixed picture, with revenue beating expectations but earnings missing due to higher wholesale penetration and an impairment charge. Wholesale revenue jumped over 50% and rose to roughly 11% of sales, helped by early spring shipments and at‑once fill‑in orders, while direct‑to‑consumer revenue climbed in the mid‑teens on the back of solid same‑store sales growth.

Poser highlights weather as an underappreciated driver of those numbers, noting that Europe and parts of North America suffered unusually cold winters that likely boosted demand for premium outerwear. Management did not explicitly credit the cold snap, but Poser sees a clear link between the frigid January and February temperatures and the strong fourth‑quarter revenue performance.

At the same time, management cited softer trends late in the quarter, blaming a more cautious consumer environment and geopolitical tensions that weighed on travel‑related and discretionary spending. Poser worries that investors may be overestimating sustainable demand if they ignore the weather boost that helped offset macro‑driven weakness and an earlier warm winter that had hurt prior results.

For investors, the upgrade to Hold suggests the worst of the valuation compression may be past, but that fundamental concerns about reliance on cold weather and volatility in wholesale versus DTC remain unresolved. GOOS, in his view, still has a lot to prove before it can reclaim premium‑growth status in the market’s eyes.

F5, Inc. (FFIV) is emerging as a quiet winner in the AI infrastructure boom, prompting Evercore ISI analyst Amit Daryanani to shift his view decisively. He has upgraded the stock to Outperform from In Line and hiked his price target to $475, implying roughly 31% upside as he now sees F5 as a high‑single‑digit revenue and low‑double‑digit EPS compounder.

Central to his bullish case is F5’s growing role in AI inference traffic, where the company already counts about $50 million in AI‑related bookings in the first half of fiscal 2026. Daryanani estimates the AI application delivery controller market could reach around $1.5 billion by 2028, with F5 capturing $400–600 million, helped by its strengths in data delivery, load balancing and runtime security across modern AI workloads.

He also points to pricing discipline as a structural growth driver rather than a one‑off lever. With the company passing along cost inflation and benefiting from similar moves by rivals like Citrix, he expects mid‑single‑digit price realization to continue, adding fuel to revenue growth while operating leverage allows a large portion of incremental sales to drop to the bottom line.

F5’s systems business has logged seven straight quarters of double‑digit growth, which Daryanani sees as an expansion cycle tied to AI, data sovereignty needs and competitive displacements, not merely a routine refresh. He argues that with a cost base skewed toward fixed operating expenses, every turn of revenue growth can meaningfully expand margins and add roughly $0.50 of EPS for each 100‑basis‑point gain.

Finally, valuation remains a big part of the bull case. F5 trades at a notable discount to networking and cybersecurity peers on both earnings and sales multiples, and Daryanani believes the gap is too wide for a company with credible AI tailwinds and a partnership with Nvidia that could be further detailed at the May 28 analyst day, positioning FFIV as a compelling way to play the infrastructure side of the AI trade.